NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.

Colossal Biosciences, the world's first de-extinction company, announces the bluebuck as the sixth species in its ...

MSCs improve therapeutic consistency and precision across cell therapies. The approach also supports scalable allogeneic ...

Inside the Destiny laboratory module aboard the International Space Station, NASA flight engineer Zena Cardman recently ...

A study identifies PCBP1 as a regulator of AARS2 function in heart cells, linking its loss to mitochondrial damage, and ...

Researchers from the Keck School of Medicine of USC have made an important advance toward understanding—and potentially treating—a rare ...

Researchers from the Keck School of Medicine of USC have made an important advance toward understanding—and potentially treating—a rare cardiomyopathy (heart muscle disease) that is present from birth ...

Scientists used a bacterial system called retron to turn DNA into a programmable tool inside living cells, enabling gene regulation and disease detection. The non-genetic DNA platform leverages a ...

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and manufacturing-ready reagent platforms are reshaping regenerative medicine and ...

Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology. “We are very ...